Alzheimer's therapeutics: translation of preclinical science to clinical drug development - Wikidata - wikimedia - TriplyDB

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

http://www.wikidata.org/entity/Q26829267

about

Optimization of touchscreen-based behavioral paradigms in mice: implications for building a battery of tasks taxing learning and memory functions Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats.Structured evaluation of rodent behavioral tests used in drug discovery research.Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease.The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries.Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.Women with the Alzheimer's risk marker ApoE4 lose Aβ-specific CD4⁺ T cells 10-20 years before men.Dementia resulting from traumatic brain injury: what is the pathology?Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice Clinical phenotype of dementia after traumatic brain injury A Novel Way of Amelioration of Amyloid Beta Induced Toxicity in Caenorhabditis elegans.Effect of flavonoids on learning, memory and neurocognitive performance: relevance and potential implications for Alzheimer's disease pathophysiology.Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.Meserine, a novel carbamate AChE inhibitor, ameliorates scopolamine-induced dementia and alleviates amyloidogenesis of APP/PS1 transgenic mice.Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers.Neurotherapeutics.Impact of Flavonoids on Cellular and Molecular Mechanisms Underlying Age-Related Cognitive Decline and Neurodegeneration.

P2860

Q28539980-E4C3C6EA-A556-45CC-9DE8-22A0C393AD50 Q30381995-464D5CF8-637D-4583-B41F-1B45451A649B Q30433294-7BCAF7B0-DA90-4950-90DB-8E433BF689F3 Q30760387-A9D04FDB-8CDD-4FCE-9B99-5E769F7521F0 Q33620099-87535099-9DCD-4BF1-A01D-A1892D17F100 Q33745617-B82C5500-1935-4B0F-9846-D035749BA70C Q33990616-2886AD89-646F-4EF1-B84A-2624D1832BBF Q34032721-A00DF2DB-424A-4A59-A920-0F938743D434 Q34948575-D54A1066-5141-4148-AF2C-2646982C5281 Q36995746-87E1C6A8-9E6B-44EB-8302-265A259AADD9 Q37298796-A6BE2123-A7BF-4223-971A-257564C21470 Q38171400-FAB95E18-7E98-40EE-A888-BFFBAA736426 Q38742951-71381087-B961-43E3-90B4-525FC266FD42 Q39054244-6C1ECA82-DDDA-478A-91FC-E2B5C09D87A2 Q39809741-791D5AB3-85AF-4634-A99B-C42EC8DC8537 Q43012020-33845804-258C-46F8-A941-458FCDAF0D01 Q55007348-7149B26D-BBE4-4052-A047-BAE9D0446435

P2860

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

http://www.wikidata.org/entity/Q26829267

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

@ast

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

@en

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

@nl

type

label

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

@ast

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

@en

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

@nl

prefLabel

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

@ast

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

@en

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

@nl

P1433

Q26829267-C18620CA-1341-45A3-88B6-4CAFA5D3EA09

P1476

Q26829267-0F5EA0A3-7A0E-4847-B77A-E4DA546B12E2

P2093

Q26829267-107D1568-794D-4105-ABA9-99CA615BF843

Q26829267-111F4EA3-CACC-43E7-AD5F-AD85E6AD915A

Q26829267-2A302650-4427-4211-B374-96768F31B3A4

Q26829267-49B52EBC-E9C1-4506-96B9-29341A4F9756

Q26829267-63A78F95-D8FA-406F-99A6-8DC841504B8D

Q26829267-A7A77212-68B3-473F-AC5E-5B59C8DF6DEB

Q26829267-D9D2DC2B-BB92-464D-AB26-878147C904BC

Q26829267-F1EBAC4B-FD39-4EA7-9248-B25F3C5B066A

P2860

Q26829267-0285A9B8-662C-4B92-8B70-1AB9F089A9F2

Q26829267-05DEA0D8-20A7-40AE-8958-D97614BE8DEE

Q26829267-05E8EC35-C0B3-4C40-AEC6-6A4CF35B5568

Q26829267-0606B242-8E62-4635-B45F-44A7243D0CB3

Q26829267-087C5566-0F4C-49AD-BC0C-8C6007DEBDA3

Q26829267-0A9A3017-40A9-4E12-A95D-D09F0286FD7E

Q26829267-0B528275-CA51-4D32-9B62-9708C8792C99

Q26829267-12D303B1-7BCA-4FAC-9C2B-76F09736AA3D

Q26829267-13417F66-A284-43EC-A111-9B508F3A6FE3

Q26829267-1607FBC6-37D8-4BFB-B0C8-11CFD98761D7

P2888

Q26829267-E9B3AD55-EF93-4465-8E9C-CDFB021A66C7

P304

Q26829267-A1179419-1D2D-43A8-927A-9A459360888C

P31

Q26829267-4F355921-E2A9-47BE-8EB6-7D46FB74B86F

P3181

Q26829267-7BBE09CC-8BA9-4AFB-95C0-1414C82F94E2

P356

Q26829267-63552ABF-F271-4BAA-8743-20EB3942C644

P407

Q26829267-036500B0-B51D-4B9A-A656-CA6DF8CA19A5

P433

Q26829267-25915921-9314-4C65-9F9F-A1F7ED39CD08

P478

Q26829267-3FCE4995-38F7-413D-BD32-D3EFFB07D47E

P577

Q26829267-69B0E8AB-9604-40C4-A49A-739E9663A751

P5875

Q26829267-3301F454-9CF3-471B-9725-CD648021E003

P6179

Q26829267-97C60EFB-A1F4-4BFF-A74A-C9316B6E78C3

P698

Q26829267-F8BF711C-7985-48DF-87AB-6CD169DEEEAE

P921

Q26829267-0F6A50DF-AD2F-4E0D-B5E8-CBC808880B38

P932

Q26829267-6EB6760A-0DC7-4E6C-9E08-EA01389E18E2

P3181

P356

P1433

Neuropsychopharmacology

P1476

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

@en

P2093

Alena V Savonenko

http://www.w3.org/2001/XMLSchema#string

Andrew Hiatt

http://www.w3.org/2001/XMLSchema#string

Don L Price

http://www.w3.org/2001/XMLSchema#string

Juan C Troncoso

http://www.w3.org/2001/XMLSchema#string

Paul F Worley

http://www.w3.org/2001/XMLSchema#string

Phil C Wong

http://www.w3.org/2001/XMLSchema#string

Tatiana Melnikova

http://www.w3.org/2001/XMLSchema#string

Tong Li

http://www.w3.org/2001/XMLSchema#string

P2860

Cholinesterase inhibitors for Alzheimer's disease

Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease

Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

BACE (beta-secretase) modulates the processing of APLP2 in vivo

Neuregulin 1 and susceptibility to schizophrenia.

Genome-wide association studies in Alzheimer's disease

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

Neuropathological stageing of Alzheimer-related changes

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

P2888

P304

261-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4948192

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NPP.2011.211

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51661711

http://www.w3.org/2001/XMLSchema#string

P6179

1008284410

http://www.w3.org/2001/XMLSchema#string

P698

21937983

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3238084

http://www.w3.org/2001/XMLSchema#string